PharmaCyte Biotech, Inc. Common Stock

Day range

$0.35 – $0.40

Open

$0.37

Prev close

$0.36

Volume

6.74K

Market cap

$3.81M

Shares out

10.74M

P/E

—

P/S

—

P/B

0.14

P/FCF

—

ROE

-130.6%

ROA

-97.8%

Debt/Equity

0.00

Div yield

8.52%

As of Oct 23, 2026

• Auditor dismissalOct 16, 2026

  On October 14, 2026, the Audit Committee ... dismissed CBIZ CPAs P.C. ("CBIZ CPAs") as the Company's independent registered public accounting firm, effective as of that date.

• Annual meeting resultsApr 2, 2026

  At the Annual Meeting, stockholders of the Company voted as set forth below on five proposals... The final voting results for each matter submitted to a vote of the Company's stockholders are as follows: Proposal 1. Election of Directors... Proposal 2. Ratification of Selection of Independent Registered Public Accounting Firm... Proposal 3. Approval of Executive Compensation... Proposal 4. Approval of Reverse Stock Split... Proposal 5. Approval of Plan Amendment.

• Listing deficiency noticeDec 5, 2025

  On December 1, 2025, PharmaCyte Biotech, Inc. (the "Company") received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") for continued listing on The Nasdaq Capital Market. The Bid Price Rule requires listed securities to maintain a minimum bid price of $1.00 per share, and, based on the closing bid price of the Company's common stock for the 30 consecutive business days preceding the date of the Notice, the Company no longer satisfies this requirement.

• Equity compensation grantOct 31, 2025

  stockholders of PharmaCyte Biotech, Inc. (the "Company") approved an amendment to the Company's 2022 Equity Incentive Plan to, among other things, increase the number of shares of the Company's common stock (the "Common Stock") available for the grant of awards by 2,250,000 shares

• Underwriting agreementAug 18, 2025

  GP Nurmenkari Inc. is acting as the placement agent for the Private Placement (the "Placement Agent"). In connection with the Private Placement, pursuant to an Engagement Letter (the "Engagement Letter") between the Company and the Placement Agent, the Company has agreed to pay the Placement Agent (i) a cash fee equal to 8.0% of the gross proceeds from any sale of securities in the Private Placement plus a non-accountable expense of $10,000, and (ii) warrants to purchase shares of Common Stock equal to 8.0% of the number of shares of common stock that the Preferred Stock are initially convertible into.

Days to cover

1.0

Short interest

133.89K

Avg volume

533.56K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Pancreatic Cancer Treatment Market Size Worth USD 10.53 Billion by 2032 Driven by Rising Prevalence of Obesity, Smoking, and Alcohol Consumption | Research by SNS Insider
  positiveGlobeNewswire Inc.· Aug 27, 2024
• Meta Platforms Announces $40 Billion Share Buyback - Buyback Wednesdays
  Seeking Alpha· Feb 9, 2023
• PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value
  GlobeNewswire Inc.· Oct 7, 2022
• Wall Street Breakfast: What Moved Markets
  Seeking Alpha· Aug 14, 2021
• The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
  Benzinga· Aug 13, 2021